Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys

Xenobiotica

Volumn 33, Issue 6, 2003, Pages 643-654

  Jin, L ^a   Chen, I W ^a   Chiba, M ^a   Lin, J H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COMPOUND A; CYTOCHROME P450 3A; INDINAVIR; N TERT BUTYL 4 (BENZOFURAN 2 YLMETHYL) 1 [2 HYDROXY 4 (2 HYDROXYINDAN 1 YLCARBAMOYL) 5 PHENYLPENTYL]PIPERAZINE 2 CARBOXAMIDE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; FIRST PASS EFFECT; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NONHUMAN; PLASMA CLEARANCE; RAT; RHESUS MONKEY; SYSTEMIC CIRCULATION;

ANIMALS; ANTIBODIES, BLOCKING; AREA UNDER CURVE; BENZOFURANS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG SYNERGISM; ENZYME INHIBITORS; HIV PROTEASE INHIBITORS; INDINAVIR; INJECTIONS, INTRAVENOUS; MACACA MULATTA; MALE; MICROSOMES, LIVER; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

ANIMALIA; CANIS FAMILIARIS; MACACA MULATTA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0038434526     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825031000089128     Document Type: Article

References (23)

1. BARR, W. H. and RIEGELMAN, S., 1970, Intestinal drug absorption and metabolism. I. Comparison of methods and models to studying physiological factors of in vitro and in vivo intestinal absorption. Journal Pharmaceutical Sciences, 59, 154-163.
2. CHEN, I.-W., VASTAG, K. J and LIN, J. H., 1995, High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. Journal of Chromatography, 672, 111-117.
3. DEUTSCH, P. J., YEH, K. C., JU, W. D., STONE, J. A., ZHONG, L., ROSE, M. J., KENNY, E., MICHIELS, N., LENS, S., ZUCKERMAN, J. and GUILLAUME, M., 2000, Pharmacokinetics and tolerability of MK-944a, a combination of a new HIV protease inhibitor with indinavir, in phase I studies. In Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections, p. 506.
4. DORSEY, B. D, MCDONOUGH, C., MCDANIEL, S. L., LEVIN, R. B., NEWTON, C. L., HOMAN, J. M., DARKE, P. L., ZUGAY-MURPHY, J. A., EMINI, E. A., SCHLEIF, W. A., OLSEN, D. B., STAHLHUT, M. W., RUTKOWSKI, C. A., KUO L. C., LIN, J. H., CHEN, I. W., MICHELSON, S. R., HOLLOWAY, M. K., HU, J. R. and VACCA, J. P., 2000, Identification of MK-944a: a second clinical candidate from hydroxylaminepentanamide isostere series of HIV protease inhibitors. Journal of Medicinal Chemistry, 43, 3386-3399.
5. GIBALDI, M. and PERRIER, D., 1982, Pharmacokinetics, 2nd edn (New York: Marcel Dekker).
6. JONES, T. E., 1997, The use of other drugs to allow a lower dosage of cyclosporin to be used: therapeutic and pharmacoeconomic considerations. Clinical Pharmacokinetics, 32, 357-637.
7. KEOGH, A., SPRATT, P., MCCOSKER, C., MACDONALD, P., MUNDAY, J. and KAAN, A., 1995, Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. New England Journal of Medicine, 333, 628-633.
8. KOUDRIAKOVA, T., IATSIMIRSKAIA, E., UTKIN, I., GANGL, E., VOUROS, P., STOROZHUK, E., ORZA, D., MARININA, J. and GERBER, N., 1998, Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metabolism and Disposition, 26, 552-561.
9. KUMAR, G. N., DYKSTRA, J., ROBERTS, E. M., JAVANTI, V. K., HICKMAN, E., UCHIC, J., TAO, Y., SURBER, B., THOMAS, S. and GRANNEMAN, G. R., 1999, Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metabolism and Disposition, 27, 902-908.
10. LIN, J. H., 1995, Species similarities and differences in pharmacokinetics. Drug Metabolism and Disposition, 23, 1008-1021.
11. LIN, J. H., 1996, In vitro and in vivo drug interaction with indinavir. Paper presented at the Symposium on Recent Advances in Drug-Drug Interaction, 10-11 December, Washington, DC.
12. LIN, J. H., 1997, Human immunodeficiency virus protease inhibitors: from drug design to clinical studies. Advanced Drug Delivery Reviews, 27, 215-233.
13. LIN, J. H., 2000, Sense and nonsense in the prediction of drug-drug interactions. Current Drug Metabolism, 1, 305-331.
14. LIN, J. H., CHIBA, M., BALANI, S. K., CHEN, I. W., KWEI, G. Y. S., VASTAG, K. J. and NISHIME, J. A., 1996, Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metabolism and Disposition, 24, 1111-1120.
15. LIN, J. H. and LU, A. Y. H., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics, 35, 361-390.
16. MEI, Q., TANG, C., ASSANG, C., LIN, Y., SLAUGHTER, D., RODRIGUES, A. D., BAILLIE, T. A., RUSHMORE, T. H. and SHOU, M., 1999, Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. Journal of Pharmacology and Experimental Therapeutics, 291, 749-759.
17. MEI, Q., TANG, C. Y., LIN, Y., RUSHMORE, T. H. and SHOU, M., 2002, Inhibition kinetics of monoclonal antibodies against cytochromes P450. Drug Metabolism and Disposition, 30, 701-708.
18. ROCCII, JR, M. L. and JUSKO, W. J., 1983, Lagran program for area and moments in pharmaceutical analysis. Computer Programs in Biomedicine, 16, 203-216.
19. SHAM, H. L., KEMPE, D. J., MOLLA, A., MARSH, K. C., KUMAR, D. N., CHEN, C. M., KATI, W., STEWART, K., LAL, R., HSU, A., BETEBENNER, D., KORNEYEVA, M., VASAVANONDA, S., MCDONALD, E., SALDIVAR, A., WIDEBURG, N., CHEN, X., NIU, P., PARK, C., JAYANTI, V., GRABOWSKI, B., GRANNEMAN, G. R., SUN, E., JAPOUR, A. J., PLATTNER, J. and NORBECK, D., 1998, ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobial Agents and Chemotherapy, 42, 3218-3234.
20. TSUNODA, S. M., VELEZ, R. L., VON MOLTKE, L. L. and GREENBLATT, D. J., 1999, Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clinical Pharmacology and Therapeutics, 66, 461-471.
21. VACCA, J. P. and CONDRAA, J. H., 1997, Clinically effective HIV-1 protease inhibitors. Drug Discovery Today, 2, 261-272.
22. WILKINSON, G. R., 1987, Clearance approaches in pharmacology. Pharmacology Reviews, 39, 1-47.
23. YEE, G. C. and MCGUIRE, T. R., 1990, Pharmacokinetic drug interaction with cyclosporin: I. Journal of Pharmacology and Experimental Therapeutics, 19, 312-332.